Haemacure Corp.
http://www.haemacure.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Haemacure Corp.
Haemacure puts up "for sale" sign
Haemacure has put itself up for sale while its hunt for financing continues to be unsuccessful. The Canadian company, which has been seeking cash since the third quarter of last year, will also suspend development of its lead candidate and reduce costs.
Haemacure makes new appointment to board of directors
The Canadian biotherapeutics company Haemacure has appointed Dr Thomas Lynch to its board of directors. Dr Lynch brings 15 years experience as a research scientist in public, academic and private sectors to the position, and whilst on the board will aid the progression to Phase II/III clinical trials for Haemacure's lead candidate, Hemaseel HMN (fibrin sealant), for biosurgical haemostasis. Dr Lynch currently serves as senior vice-president of compliance, regulatory affair and public policy for Talecris Biotherapeutics; prior to this he was vice-president of regulatory affair and quality assurance at CryoLife.
Renovo's Juvista succeeds in Phase II, but development plans disappoint
Renovo's scar-healing treatment Juvista (human recombinant TGF beta
Renovo given EU thumbs up for Juvista for Phase III
Renovohas received positive feedback from the EU's CHMPregarding its plans for Phase III development of the scar-reduction treatment Juvista.
Company Information
- Industry
- Biotechnology
-
Medical Devices
- Biomaterials
-
Surgical Equipment & Devices
- Surgical Sealants
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice